Authors
Latest:
Navigating Unplanned Value Inflection Points in International AlliancesDealing with significant unplanned events in alliances is important work. It's is critical to maintain the ongoing health of the alliance by applying sound governance principles and minimizing the disruption to normal operations wherever possible. So how can you stabilize your ships in rough seas?
Latest:
Navigating Unplanned Value Inflection Points in International AlliancesDealing with significant unplanned events in alliances is important work. It's is critical to maintain the ongoing health of the alliance by applying sound governance principles and minimizing the disruption to normal operations wherever possible. So how can you stabilize your ships in rough seas?
Latest:
Navigating Unplanned Value Inflection Points in International AlliancesDealing with significant unplanned events in alliances is important work. It's is critical to maintain the ongoing health of the alliance by applying sound governance principles and minimizing the disruption to normal operations wherever possible. So how can you stabilize your ships in rough seas?
Latest:
The Benefits of IT Outsourcing in Life SciencesFrom lightweight ERP work, to break fix services, to infrastructure- how start-up life sciences organizations, or those new to the outsourcing model, are benefiting from the use of IT partners.
Latest:
Don't Be a COVID Copycat: Digital Engagement is Not EnoughEven before COVID-19, over 50% of pharma companies were piloting or using virtual and live remote e-detailing as standard practice. Companies need to go further to have a real impact, writes Rasim Shah.
Latest:
Iraq: Stabilizing a Growing MarketAli Mosawi writes about the misconceptions of Iraq's often inhospitable landscape, the essential role of international expertise in driving growth, and how the sector has adapted to meet the challenges of the COVID-19 pandemic.
Latest:
COVID-19: Testing Biotech's Ingenuity in New WaysStartup biotechs need to ensure that life-changing and potentially lifesaving treatments continue to be developed in in the midst of the COVID-19 pandemic. Ohana Biosciences' Amber Salzman outlines how her company is
Latest:
How to Leverage Pricing Governance to Safeguard the ToplineWhile crucial, product-level brand strategies or launch strategies are not sufficient to ensure the long-term success of a product. Best-in-class companies are set apart by their internal pricing governance, write Stephan Schurz and Dr. Fangting Yu.
Latest:
Making the Most of Social Media (Within FDA’s New Guidelines)Pharmaceutical companies have begun using social media for business needs and promotion, yet have been hesitant to become too engaged since the FDA’s stance on social media activity remained unclear.
Latest:
How Life Sciences Companies Can Promote Greater Medication Adherence During COVID19Life sciences companies have an essential role in partnering with providers to deliver targeted communications about medication efficacy and adherence – not only where COVID-19 is well-established, but alsoin areas of emerging risk.
Latest:
A Sustainable Response to COVID-19Three areas critical to ensuring meaningful long-term action.
Latest:
Drug Development in Wartime: Driving Tomorrow's R&D Decisions with Today's COVID-19 DataThe only way for pharma companies to know where to focus their COVID-19 R&D efforts is for the industry to have access to real-time, real-world evidence of what’s working to keep people alive, write Travis Leonardi and William Kirsh.
Latest:
A Better Path to Payer InsightsPayers have transformed the competitive marketplace, and biopharma companies need to regain their position as the authority on their products. To do this, they must establish new ways to anticipate, identify, and react to payer impressions of relevant evidence as they occur.
Latest:
Is Pharma Too Introspective to be Truly Innovative?Every major pharma company undertakes some form of diversity and inclusion work. However, that doesn’t mean it’s reaching the decision-makers, writes Stephen Frost.
Latest:
Coordinating Data and Analytics Ownership with Payers and ProvidersMatthew Sussman explores strategies for facilitating access to the timely patient data and analysis needed for successful value-based agreements between manufacturers, payer and provider organizations in 2020 and beyond.
Latest:
How to Ride the Data Wave When Launching a New DrugHow exactly do pharma companies account for a gap between their hopes for a new drug and reality? Peter Harbin reports.
Latest:
COVID & Chronic Disease: Meeting the Needs of Vulnerable PatientsPharma companies are in a unique position to support and educate at-risk populations through patient services hubs.
Latest:
Make Content Work Harder from Start to FinishA centralized platform for assets supports the industry’s need for a greater volume of more diverse content, writes Callum Hawes.
Latest:
Keys to Successful Virtual Medical MeetingsWith medical meetings and congresses going virtual in the face of COVID-19, how do pharma companies put together a strategic plan for a new format that meets goals while remaining sensitive to the broader environment?
Latest:
Navigating the Recession and Patent ExpirationsPharma is built to overcome, but focus on fundamentals remains key.
Latest:
Digital Engagement With Physicians and Other Healthcare ProfessionalsWhenever you hear “tried-and-true” used to describe a strategy, tactic, workshop, or any other fundamental step required to achieve market domination-ask the speaker what year it is.
Latest:
Niche Online Programming Amid COVID-19 for Oncology PharmaCancer patients are now utilizing online programming made available by Patient Power as a source for expert analysis.
Latest:
Evolve the Role of Reimbursement Policy to Meet the Needs of the New Market Access EcosystemChance Scott shares insights on the benefits of evolving the role and integration of your reimbursement policy team to serve as market access partners and propellants, as well as the best practices for how to do so.
Latest:
The Myth of Skyrocketing Drug Prices: A Closer Look at The US Gross to Net ProblemWhile there has been an increase in discourse concerning drug pricing transparency in recent years, there is still a degree of misunderstanding. This is due to the healthcare industry's numerous stakeholders and their compelling interests. This research done by Guidehouse aims to clear the picture.
Latest:
The Myth of Skyrocketing Drug Prices: A Closer Look at The US Gross to Net ProblemWhile there has been an increase in discourse concerning drug pricing transparency in recent years, there is still a degree of misunderstanding. This is due to the healthcare industry's numerous stakeholders and their compelling interests. This research done by Guidehouse aims to clear the picture.
Latest:
Pricing for Rare Disease and Curative Therapies: What’s Fair?There has been a considerable amount of attention given to the rising costs of pharmaceutical and biotechnology therapies in the US. In early 2020, Charles River Associates conducted this research to determine what "fair" prices would be for these therapies.
Latest:
Reducing Prescription Drug Costs for Seniors: The ABCs of ASP for Part DOutlining the steps to a payment approach for Medicare Part D drugs that provides savings for patients.
